


# The COALA (Cure Oncogene-Addicted Lung Adenocarcinoma) research network: a nationwide consortium dedicated to improving lung cancer outcomes

J. Mazieres<sup>1</sup>, V. Albinet<sup>1</sup>, O. Calvayrac<sup>2</sup>, M. Alifano<sup>3</sup>, S. Benzekry<sup>4</sup>, A. Cortot<sup>5</sup>, D. Damotte<sup>3</sup>, M. Duruisseaux<sup>6</sup>, L. Fernandez-Cuesta<sup>7</sup>, L. Friboulet<sup>8</sup>, N. Girard<sup>9</sup>, P. Hofman<sup>10</sup>, A. Maraver<sup>11</sup>, S. Ortiz-Cuaran<sup>12</sup>, V. Pancaldi<sup>2</sup>, A. Swalduz<sup>12</sup>, E. Tartour<sup>13</sup>, A. Vézian<sup>14</sup>, V. Westeel<sup>15</sup>, M. Wislez<sup>3</sup>, G. Zalcman<sup>16</sup>

<sup>1</sup>Toulouse University Hospital, Toulouse, FRANCE, <sup>2</sup>Cancer Research Center of Toulouse (CRCT), Université de Toulouse, Inserm, CNRS, Toulouse, FRANCE, <sup>3</sup>Cordeliers Research Center, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE, <sup>4</sup>INRIA, COMPO, Marseille, FRANCE, <sup>5</sup>Lille Interdisciplinary Cancer Research Institute (ONCOLille), Lille University Hospital, Lille, FRANCE, <sup>6</sup>Hospices Civils de Lyon, Cancer Research Center of Lyon, Lyon, FRANCE, <sup>7</sup>International Agency for Research on Cancer/World Health Organisation (IARC/WHO), Lyon, FRANCE, <sup>8</sup>Université Paris-Saclay, Gustave Roussy, Inserm U981, Villejuif, FRANCE, <sup>9</sup>Institut Curie, U932, Paris, FRANCE, <sup>10</sup>IHU RespirERA, Côte d'Azur University, Nice, FRANCE, <sup>11</sup>IRCM, Montpellier, FRANCE, <sup>12</sup>Univ Lyon, Claude Bernard Lyon 1 University, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, FRANCE, <sup>13</sup>AP-HP, Hôpital Européen Georges Pompidou, Paris, FRANCE, <sup>14</sup>Centre national de la recherche scientifique (CNRS), École Nationale Supérieure (ENS), Lyon, FRANCE, <sup>15</sup>Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, FRANCE, <sup>16</sup>Institut Curie, Centre de Recherche, UMR 1139 INSERM, Chemical Biology of Cancer, Paris, FRANCE.




www.coala-lung.org



COALA LABREXCOMP24-001 – Inca\_18791

COALA is a French multidisciplinary research network dedicated to significantly improving the therapeutic management of patients with lung adenocarcinoma harboring targetable alterations.




**Understand** the disease & the patients through a multidisciplinary approach  
**Improve** treatments  
**Prevent** the emergence of resistances  
**Cure** patients with oncogene-addicted lung cancer

## Key figures

Consortium	Budget	Duration	Start date
15 teams	3 million €	5 years	April 17, 2024

Project coordinator: Pr. Julien Mazières



## Lung cancer: new opportunities, new challenges

Over the last decades, the development of new anti-cancer treatments has revolutionized the standard of care for patients with lung cancer, particularly those with genetic alterations in 'driver' oncogenes such as EGFR, ALK, ROS1, BRAF or more recently KRAS. Despite these advances, long-term disease control remains challenging due to the frequent onset of therapeutic resistance. Not all patients respond equally to treatment—this variability may stem from the molecular characteristics of their tumors, the limited efficacy of available therapies, or a range of individual-specific factors. Therefore, it is essential to integrate diverse approaches to better understand tumor response to treatment, with the goal of extending therapeutic benefit in good responders and enhancing efficacy in those who respond poorly.

## Our mission

We have built a multidisciplinary consortium to significantly improve the therapeutic management of patients with lung adenocarcinoma harboring targetable alterations. We have defined 6 complementary work packages to join efforts across disciplines through translational research, optimize personalized strategies, and disseminate cutting-edge knowledge.

